Brief: Lantern Pharma Expands AI Capabilities Of RADR Platform To Accelerate Clinical Development Of Immune Checkpoint Inhibitors
28/08/2023 14:19
Aug 28 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA EXPANDS AI CAPABILITIES OF RADR® PLATFORM
TO
ACCELERATE THE CLINICAL DEVELOPMENT OF IMMUNE CHECKPOINT
INHIBITORS
Source text for Eikon: ID:nBw5CRnPGa
Further company coverage: LTRN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview